Andreas Halvorsen: portfolio of Viking Global Investors
Andreas Halvorsen leads Viking Global Investors, a hedge fund that analyzes stocks worldwide and combines long and short positions.
Source: 13F filing with the US Securities and Exchange Commission dated Feb 14, 2023. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included. Form 13F filingInvestment managers with discretion over at least 100 million USD in reportable US securities (mainly stocks and ETFs, plus options and convertible bonds) report their holdings to the SEC within 45 days after each quarter. Short positions, securities traded only abroad and cash are not included.Example: Positions as of 30 Sep, filed on 14 Nov → they are already six weeks old when published.More in the Academy: Glossary
You are looking at Q4 2022. Go to the latest filing (Q3 2026)
- Total value of stock positions
- 19.9B USD
- Positions
- 75
- Share of the ten largest
- 41.8%
The ten largest positions Q4 2022
- Visa Inc. 6.0%▲ +8.2%
- Amazon 5.3%▲ +34.4%
- Elevance Health 4.8%▼ −19.9%
- McKesson Corporation 4.2%▼ −15.5%
- Microsoft 4.1%▼ −2.3%
- Chubb Limited 4.0%▼ −0.4%
- Roivant Sciences Ltd 3.5%unchanged
- UnitedHealth Group 3.4%▲ +263.7%
- GE Aerospace 3.3%▼ −39.6%
- Api Group Corp 3.2%unchanged
Show all positions of this quarter
Choose a quarter (54 filings)
- Q3 2026
- Q2 2026
- Q1 2026
- Q4 2025
- Q3 2025
- Q2 2025
- Q1 2025
- Q4 2024
- Q3 2024
- Q2 2024
- Q1 2024
- Q4 2023
- Q3 2023
- Q2 2023
- Q1 2023
- Q4 2022
- Q3 2022
- Q2 2022
- Q1 2022
- Q4 2021
- Q3 2021
- Q2 2021
- Q1 2021
- Q4 2020
- Q3 2020
- Q2 2020
- Q1 2020
- Q4 2019
- Q3 2019
- Q2 2019
- Q1 2019
- Q4 2018
- Q3 2018
- Q2 2018
- Q1 2018
- Q4 2017
- Q3 2017
- Q2 2017
- Q1 2017
- Q4 2016
- Q3 2016
- Q2 2016
- Q1 2016
- Q4 2015
- Q3 2015
- Q2 2015
- Q1 2015
- Q4 2014
- Q3 2014
- Q2 2014
- Q1 2014
- Q4 2013
- Q3 2013
- Q2 2013
All positions Q4 2022
| Symbol | Weight | Shares | Reported value | Change | Held since |
|---|---|---|---|---|---|
| V Visa Inc. | 6.0% | 5,784,971 | 1.2B USD | +8.2% increased | Q3 2016 26 quarters |
| AMZN Amazon | 5.3% | 12,481,958 | 1.0B USD | +34.4% increased | Q2 2015 31 quarters |
| ELV Elevance Health | 4.8% | 1,872,176 | 960.4M USD | −19.9% reduced | Q1 2022 4 quarters |
| MCK McKesson Corporation | 4.2% | 2,204,418 | 826.9M USD | −15.5% reduced | Q2 2022 3 quarters |
| MSFT Microsoft | 4.1% | 3,429,127 | 822.4M USD | −2.3% reduced | Q2 2016 27 quarters |
| CB Chubb Limited | 4.0% | 3,580,128 | 789.8M USD | −0.4% reduced | Q1 2020 12 quarters |
| Roivant Sciences Ltd | 3.5% | 88,238,700 | 705.0M USD | unchanged | Q4 2021 5 quarters |
| UNH UnitedHealth Group | 3.4% | 1,267,703 | 672.1M USD | +263.7% increased | Q3 2022 2 quarters |
| GE GE Aerospace | 3.3% | 7,775,177 | 651.5M USD | −39.6% reduced | Q4 2020 9 quarters |
| Api Group Corp | 3.2% | 33,819,567 | 636.1M USD | unchanged | Q2 2020 11 quarters |
| MA Mastercard | 3.0% | 1,709,228 | 594.3M USD | −3.5% reduced | Q1 2022 4 quarters |
| Hdfc Bank Ltd | 2.9% | 8,570,740 | 586.3M USD | −11.8% reduced | Q3 2021 6 quarters |
| Biomarin Pharmaceutical Inc | 2.7% | 5,273,620 | 545.8M USD | +3.4% increased | Q4 2021 5 quarters |
| AMP Ameriprise Financial | 2.6% | 1,647,855 | 513.1M USD | −8.7% reduced | Q1 2021 8 quarters |
| CSX CSX Corporation | 2.4% | 15,548,123 | 481.7M USD | new | Q4 2022 1 quarter |
| TMO Thermo Fisher Scientific | 2.3% | 839,526 | 462.3M USD | +41.4% increased | Q2 2020 11 quarters |
| INTU Intuit | 2.3% | 1,181,697 | 459.9M USD | +2.1% increased | Q2 2022 3 quarters |
| BSX Boston Scientific | 2.2% | 9,528,593 | 440.9M USD | −41.0% reduced | Q3 2018 18 quarters |
| MU Micron Technology | 2.1% | 8,358,708 | 417.8M USD | +54.4% increased | Q2 2022 3 quarters |
| Royalty Pharma PLC | 2.0% | 10,008,511 | 395.5M USD | −8.0% reduced | Q2 2020 11 quarters |
| FTNT Fortinet | 1.8% | 7,126,827 | 348.4M USD | new | Q4 2022 1 quarter |
| Seagate Technology Hldngs Pl | 1.6% | 6,198,933 | 326.1M USD | new | Q4 2022 1 quarter |
| META Meta Platforms | 1.4% | 2,387,730 | 287.3M USD | −55.4% reduced | Q4 2020 9 quarters |
| XYZ Block, Inc. | 1.4% | 4,483,754 | 281.8M USD | −15.6% reduced | Q4 2021 5 quarters |
| Acadia Healthcare Company In | 1.3% | 3,161,114 | 260.2M USD | +6.8% increased | Q4 2020 9 quarters |
| FTV Fortive | 1.3% | 3,890,600 | 250.0M USD | −36.0% reduced | Q3 2019 14 quarters |
| Karuna Therapeutics Inc | 1.2% | 1,183,736 | 232.6M USD | +16.7% increased | Q3 2020 10 quarters |
| Adaptive Biotechnologies Cor | 1.2% | 29,993,708 | 229.2M USD | unchanged | Q2 2019 15 quarters |
| Brookfield Corp | 1.1% | 7,262,078 | 228.5M USD | new | Q4 2022 1 quarter |
| Rogers Comms B | 1.0% | 4,375,144 | 204.8M USD | +29.5% increased | Q3 2022 2 quarters |
| Bridgebio Pharma Inc | 1.0% | 26,620,991 | 202.9M USD | unchanged | Q2 2019 15 quarters |
| Rh | 1.0% | 748,344 | 200.0M USD | +80.4% increased | Q2 2022 3 quarters |
| UBER Uber | 1.0% | 7,939,999 | 196.4M USD | −51.6% reduced | Q3 2021 6 quarters |
| Molina Healthcare Inc | 1.0% | 588,208 | 194.2M USD | +44.6% increased | Q3 2019 14 quarters |
| LI Li Auto | 0.9% | 9,090,065 | 185.4M USD | new | Q4 2022 1 quarter |
| CDNS Cadence Design Systems | 0.9% | 1,134,301 | 182.2M USD | +87.3% increased | Q3 2022 2 quarters |
| Amylyx Pharmaceuticals Inc | 0.9% | 4,634,606 | 171.2M USD | −19.7% reduced | Q1 2022 4 quarters |
| AIG American International Group | 0.8% | 2,590,026 | 163.8M USD | new | Q4 2022 1 quarter |
| Inhibrx Inc | 0.8% | 6,639,199 | 163.6M USD | +25.1% increased | Q3 2020 10 quarters |
| Valvoline Inc | 0.8% | 4,876,780 | 159.2M USD | −16.6% reduced | Q3 2022 2 quarters |
| Equitable HLDGS Inc | 0.8% | 5,212,460 | 149.6M USD | new | Q4 2022 1 quarter |
| Unum Group | 0.7% | 3,431,274 | 140.8M USD | −32.4% reduced | Q1 2022 4 quarters |
| Inspire Med Sys Inc | 0.7% | 549,793 | 138.5M USD | −13.2% reduced | Q1 2022 4 quarters |
| AMD Advanced Micro Devices | 0.6% | 1,905,600 | 123.4M USD | new | Q4 2022 1 quarter |
| BEKE KE Holdings | 0.6% | 8,084,334 | 112.9M USD | +107.6% increased | Q4 2021 5 quarters |
| CRL Charles River Laboratories | 0.6% | 515,168 | 112.3M USD | −21.8% reduced | Q1 2021 8 quarters |
| Guardant Health Inc | 0.6% | 4,107,644 | 111.7M USD | +7.1% increased | Q3 2019 14 quarters |
| CLX Clorox | 0.5% | 768,839 | 107.9M USD | +26.7% increased | Q3 2022 2 quarters |
| Ginkgo Bioworks Holdings Inc | 0.5% | 63,085,126 | 106.6M USD | −38.1% reduced | Q3 2021 6 quarters |
| 4D Molecular Therapeutics In | 0.4% | 3,937,914 | 87.5M USD | unchanged | Q4 2020 9 quarters |
| PODD Insulet Corporation | 0.4% | 268,052 | 78.9M USD | −56.1% reduced | Q3 2020 10 quarters |
| DG Dollar General | 0.4% | 310,848 | 76.5M USD | −87.2% reduced | Q1 2022 4 quarters |
| CRWD CrowdStrike | 0.4% | 699,948 | 73.7M USD | +146.2% increased | Q3 2022 2 quarters |
| ALB Albemarle Corporation | 0.4% | 337,339 | 73.2M USD | new | Q4 2022 1 quarter |
| Intellia Therapeutics Inc | 0.4% | 2,021,410 | 70.5M USD | +7.0% increased | Q2 2021 7 quarters |
| Catalent Inc | 0.3% | 1,424,388 | 64.1M USD | −14.9% reduced | Q1 2018 20 quarters |
| Zai Lab Ltd | 0.3% | 1,973,597 | 60.6M USD | −24.5% reduced | Q1 2021 8 quarters |
| Kbr Inc | 0.3% | 1,077,300 | 56.9M USD | new | Q4 2022 1 quarter |
| Capri Holdings Limited | 0.2% | 810,479 | 46.5M USD | new | Q4 2022 1 quarter |
| IFF International Flavors & Fragrances | 0.2% | 439,360 | 46.1M USD | −88.2% reduced | Q4 2021 5 quarters |
| PGR Progressive Corporation | 0.2% | 336,861 | 43.7M USD | −54.3% reduced | Q1 2022 4 quarters |
| Regal Rexnord Corporation | 0.2% | 362,403 | 43.5M USD | new | Q4 2022 1 quarter |
| Newamsterdam Pharma Company | 0.2% | 3,753,828 | 39.5M USD | new | Q4 2022 1 quarter |
| Edgewise Therapeutics Inc | 0.2% | 4,409,146 | 39.4M USD | unchanged | Q1 2021 8 quarters |
| Pharvaris N V | 0.2% | 3,231,923 | 36.4M USD | +29.4% increased | Q1 2021 8 quarters |
| Shockwave Med Inc | 0.2% | 164,607 | 33.8M USD | +4.6% increased | Q2 2022 3 quarters |
| Day One Biopharmaceuticals I | 0.2% | 1,558,563 | 33.5M USD | unchanged | Q2 2021 7 quarters |
| Farfetch Ltd | 0.2% | 6,771,235 | 32.0M USD | new | Q4 2022 1 quarter |
| Rallybio Corp | 0.1% | 4,194,777 | 27.6M USD | unchanged | Q3 2021 6 quarters |
| Pepgen Inc | 0.1% | 1,544,631 | 20.7M USD | −13.9% reduced | Q2 2022 3 quarters |
| Kinnate Biopharma Inc | < 0.1% | 1,820,462 | 11.1M USD | unchanged | Q4 2020 9 quarters |
| Trevi Therapeutics Inc | < 0.1% | 4,400,000 | 8.5M USD | unchanged | Q3 2022 2 quarters |
| Lianbio | < 0.1% | 3,564,173 | 5.8M USD | unchanged | Q4 2021 5 quarters |
| Verastem Inc | < 0.1% | 9,224,000 | 3.7M USD | unchanged | Q2 2022 3 quarters |
| Talaris Therapeutics Inc | < 0.1% | 3,289,617 | 3.4M USD | unchanged | Q2 2021 7 quarters |
“Held since”: the first quarter from which the position appears in the 13F filing at every quarter end. It first appears at the end of that quarter – the filing gives neither date nor price, and trading between two quarter ends is not visible. “Or earlier”: the position was already in the first available filing (or the first one after a gap in filings). After a change of the security identifier (e.g. a renaming) the start may appear later.
Plus 1 position in convertible bonds and bonds worth 75.2M USD as reported – not included in the weights.
Convertible bonds and bonds, principal amount as reported. They are not stock positions and therefore do not count towards the weights.
- Guardant Health Inc principal 120.0M USD 75.2M USD
Breakdown by sector
- Financials 18.0%
- Health Care 17.9%
- Technology 12.2%
- Industrials 7.9%
- Consumer Discretionary 5.3%
- Communication Services 1.4%
- Consumer Staples 0.9%
- Materials 0.6%
- not in our coverage 35.7%
Sectors only for stocks we cover; the rest is grouped under “not in our coverage”.
How to read this page
- Weight: a position’s share of the total value of all reported stock positions in this quarter – options and bonds are not counted.
- Change: number of shares compared with the previous quarter. After a stock split we convert the previous quarter’s share count so that a split does not look like an increase; if a possible split cannot be confirmed, “–” is shown.
- Reported value: value of the position at quarter end as reported by the investor. The portfolio may have changed since then.
All superinvestor portfolios Screener: stocks held by superinvestors